

**AMENDMENT TO
RULES COMMITTEE PRINT 118-10
OFFERED BY MR. BUCK OF COLORADO**

Page 1033, after line 14, add the following new section:

1 **SEC. 18___. SENSE OF CONGRESS REGARDING MDMA-AS-**
2 **SISTED THERAPY AS TREATMENT FOR PTSD.**

3 It is the sense of Congress that—

4 (1) 3,4-Methylenedioxy-methamphetamine-as-
5 sisted therapy (in this section referred to as
6 “MDMA-AT”) should be recognized as a treatment
7 for post-traumatic stress disorder (in this section re-
8 ferred to as “PTSD”);

9 (2) MDMA-AT has shown great scientific
10 promise for treating complex, chronic PTSD, as evi-
11 denced by MDMA-AT being designated as a break-
12 through therapy under section 506 of the Federal
13 Food, Drug, and Cosmetic Act (21 U.S.C. 356) in
14 2017 for its use in conjunction with talk therapy to
15 treat PTSD;

16 (3) the potential of MDMA-AT was confirmed
17 in 2021, when the world’s first phase 3 randomized,
18 double-blind, placebo-controlled trial found that after

1 3 MDMA-AT sessions, 67 percent of participants no
2 longer qualified for a PTSD diagnosis, and 88 per-
3 cent experienced a clinically significant reduction in
4 symptoms;

5 (4) additional phase 3 clinical trial results fur-
6 ther confirmed these findings, and full approval of
7 MDMA-AT under the Federal Food, Drug, and Cos-
8 metic Act (21 U.S.C. 301 et seq.) is now expected
9 in 2024;

10 (5) thanks to significant private funding, the
11 Nation's leading academic institutions (including
12 Johns Hopkins University, Yale University, Harvard
13 University, and Stanford University) and govern-
14 mental institutions (including the Department of
15 Veterans Affairs, the National Institutes of Health,
16 and the Food and Drug Administration) have re-
17 searched MDMA-AT's potential for treating PTSD
18 for the past 2 decades; and

19 (6) MDMA-AT is a worthwhile investment in
20 the mental health of the Nation's veterans.

